Last reviewed · How we verify
MG56 Mannosylated 5000 sublingual — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
MG56 Mannosylated 5000 sublingual (MG56 Mannosylated 5000 sublingual) — Inmunotek S.L..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MG56 Mannosylated 5000 sublingual TARGET | MG56 Mannosylated 5000 sublingual | Inmunotek S.L. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MG56 Mannosylated 5000 sublingual CI watch — RSS
- MG56 Mannosylated 5000 sublingual CI watch — Atom
- MG56 Mannosylated 5000 sublingual CI watch — JSON
- MG56 Mannosylated 5000 sublingual alone — RSS
Cite this brief
Drug Landscape (2026). MG56 Mannosylated 5000 sublingual — Competitive Intelligence Brief. https://druglandscape.com/ci/mg56-mannosylated-5000-sublingual. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab